Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: A Prospective Comparison Between Serotonin Reuptake Inhibitors
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
BACKGROUND: The effect of extended anti-depressant treatment on weight has been poorly investigated. Also unknown is whether different compounds have differential effects. The aim of the present study was to assess changes in weight in obsessive-compulsive disorder (OCD) patients treated for 2.5 years with clomipramine or selective serotonin reuptake inhibitors. METHOD: 138 DSM-IV OCD patients who responded to 6-month acute treatment at the Mood and Anxiety Disorders Unit, Department of Neuroscience, University of Turin, Italy, were followed-up for 2 years while receiving open-label clomipramine, citalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. Patients were consecutively recruited and followed from May 1998 to March 2003. The mean percentage change in weight was compared for each group, as was the proportion of patients who had a > or = 7% weight increase from baseline. RESULTS: At the end of the 2.5-year study period, patients had gained a mean of 2.5% of their body weight with respect to baseline (1.58 kg); 14.5% of the total sample experienced a significant (> or = 7%) weight increase. Within each but the fluoxetine treatment group, paired t tests showed a significant increase in weight from baseline to final visit. Analysis of variance showed a significant difference between treatment groups (p = .009), with clomipramine being associated with the highest weight increase and fluoxetine and sertraline with the lowest. A higher proportion of clomipramine-treated patients (34.8%) gained > or = 7% in weight as compared with sertraline and fluoxetine, which accounted for the lowest percentage of patients with a significant weight gain (4.5% and 8.7%, respectively), although this difference was not statistically significant. CONCLUSION: Risk of weight gain during extended serotonin reuptake inhibitor treatment for OCD differs depending on which compound is used. The differences among antiobsessive drugs may affect compliance with medication and health risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although widely used and efficacious [8–10], SRI use long-term is associated with adverse side effects [11–14]”
From Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods (2018) · cites this paper as [14]
Citations
Cited by
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
“…OCD (N=138) 2 years after they had completed a 6-month treatment period with clomipramine or SSRIs (not including escitalopram) found clomipramine associated with the greatest weight increase (2.9±2.6 kg), and fluoxetine (0.5±2.4 kg) and sertraline (1.0±1.7 kg) with the least (Maina et al. 2004).”
BackgroundInfluentialDepression and the Link with Cardiovascular Disease
Dhar, A. K., & Barton, D. A. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00033 · Cited by 400
Antidepressant Medications and Weight Change: A Narrative Review
Gill, H., Gill, B., El‐Halabi, S., Chen‐Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., Majeed, A., et al. (2020) · Obesity · doi:10.1002/oby.22969 · Cited by 193
“Moreover, a review of medical health records found the least long-term weight change in patients using fluoxetine compared with other SSRIs.”
BackgroundInfluentialEvidence-based pharmacological treatment of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001434 · Cited by 168
“In a naturalistic study of SSRI-treated patients with obsessive compulsive disorder, between 4.5% (sertraline) and 14.3% (citalopram, paroxetine) had clinically significant weight gain (i.e. >7% of baseline body weight) (Maina et al. 2004).”
BackgroundInfluentialUpdate in the methodology of the chronic stress paradigm: internal control matters
Strekalova, T., Couch, Y., Kholod, N., Boyks, M., Malin, D., Leprince, P., & Steinbusch, H. M. (2011) · Behavioral and Brain Functions · doi:10.1186/1744-9081-7-9 · Cited by 163
“Restoration of body weight by antidepressant treatment, particularly citalopram, in animal models of depression has been shown to to accompany recovery from a depressive-like state [ 130 ].”
BackgroundAlbert, U., Bogetto, F., Maina, G., Saracco, P., Brunatto, C., & Mataix‐Cols, D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.06.008 · Cited by 175
“…of a semistructured interview, developed and used in previous studies (Bogetto et al., 1999; Albert et al., 2002; Albert et al., 2004; Maina et al., 2004), with a format that covered the following areas: (a) Socio-demographic data: age, sex, marital status (single, married, divorced,…”
MethodSelf-citationSkapinakis, P., Caldwell, D., Hollingworth, W., Bryden, P., Fineberg, N., Salkovskis, P., Welton, N., Baxter, H., Kessler, D., Churchill, R., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20430 · Cited by 134
Eating Disorder and Metabolism in Narcoleptic Patients
Chabas, D., Foulon, C., Gonzalez‐Bermejo, J., Nasr, M., Lyon‐Caen, O., Willer, J. C., Derenne, J., & Arnulf, I. (2007) · SLEEP · doi:10.1093/sleep/30.10.1267 · Cited by 140
Review: Bupropion and SSRI-induced side effects
Demyttenaere, K., & Jaspers, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107083798 · Cited by 132
“The proportion of patients with a 7% weight increase was 4.5 and 8.7% for sertraline and fluoxetine respectively, 14.3, 10.7 and 14.3% for citalopram, fluvoxamine and paroxetine respectively and 34.8% for clomipramine (Maina et al., 2004).”
BackgroundInfluentialStrekalova, T., Gorenkova, N., Schunk, E., Dolgov, O., & Bartsch, D. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200605000-00008 · Cited by 130
“Restoration of body weight in animal models of depression is known to accompany a recovery from a depression-like syndrome, induced by antidepressant treatment, in particular, by citalopram administration (Bouwer and Harvey, 1996; Maina et al., 2004).”
BackgroundEvidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 129
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Treating Chronic Pain with SSRIs: What Do We Know?
Patetsos, E., & Horjales-Araujo, E. (2016) · Pain Research and Management · doi:10.1155/2016/2020915 · Cited by 115
Brown, A. D. H., Barton, D. A., & Lambert, G. W. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00004 · Cited by 126
Tolerability and safety of fluvoxamine and other antidepressants
Westenberg, H. G. M., & Sandner, C. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00865.x · Cited by 103
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
Surging trends in prescriptions and costs of antidepressants in England amid COVID-19
Rabeea, S. A., Merchant, H. A., Khan, M. U., Kow, C. S., & Hasan, S. S. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00390-z · Cited by 125
Clinical predictors of health-related quality of life in obsessive-compulsive disorder
Albert, U., Maina, G., Bogetto, F., Chiarle, A., & Mataix‐Cols, D. (2009) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2009.03.004 · Cited by 114
Self-citationMattioli, L., Funari, C., & Perfumi, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089872 · Cited by 91
Maina, G., Rosso, G., Zanardini, R., Bogetto, F., Gennarelli, M., & Bocchio‐Chiavetto, L. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.07.009 · Cited by 106
“Patient data were obtained through the administration of a semistructured interview that we developed and used in previous studies (Maina et al., 2004 and Maina et al., 2008), with a format that covered the following areas: a) Socio-demographic characteristics b) BMI c) Diagnostic evaluation:…”
MethodSelf-citationThe Impact of General Medical Conditions in Obsessive-Compulsive Disorder
Aguglia, A., Signorelli, M. S., Albert, U., & Maina, G. (2018) · Psychiatry Investigation · doi:10.30773/pi.2017.06.17.2 · Cited by 85
Self-citationBokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
“Studies of escitalopram are in the literature.98-100 Citalopram and escitalopram have minimal inhibitory activity on the CYP, which is an advantage over other SSRIs.101 Citalopram and escitalopram can produce QTc prolongation, especially in overdose.102 Torsades de pointes is a life-threatening development of a prolon…”
BackgroundInfluentialMetabolic syndrome and obsessive–compulsive disorder: a naturalistic Italian study
Albert, U., Aguglia, A., Chiarle, A., Bogetto, F., & Maina, G. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.10.004 · Cited by 79
“Moreover, the use of antidepressants (selective serotonin reuptake inhibitors and clomipramine) over the long-term is also associated, independently from the association of antipsychotics, with a significant weight gain [40].”
BackgroundSelf-citationMedications Associated with Weight Gain
Malone, M. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g333 · Cited by 72
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
Current trends in drug treatment of obsessive–compulsive disorder
Decloedt, E. H., & Stein, D. J. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3149 · Cited by 74
H1-histamine receptor affinity predicts weight gain with antidepressants
Salvi, V., Mencacci, C., & Barone‐Adesi, F. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.012 · Cited by 77
“…the highest weight gain at the end of follow-up, with a 34.9% of patients displaying an increase Z7% body weight, also SSRIs had different likelihood in inducing weight gain, with paroxetine and fluvoxamine inducing more weight gain, and fluoxetine and sertraline the least (Maina et al., 2004).”
InfluentialSelf-citationBrattström, A. (2009) · Phytomedicine · doi:10.1016/j.phymed.2008.12.023 · Cited by 62
“Although there are differences among different SSRI treatments, weight gain in general is a recognized problem (Fava et al. 2000; Maina et al. 2004; Sussman et al. 2001).”
BackgroundBipolar obsessive‐compulsive disorder and personality disorders
Maina, G., Albert, U., Pessina, E., & Bogetto, F. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00508.x · Cited by 48
Self-citationEarly-onset obsessive–compulsive disorder and personality disorders in adulthood
Maina, G., Albert, U., Salvi, V., Pessina, E., & Bogetto, F. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2006.08.003 · Cited by 56
Self-citationNarcolepsy and sleep‐disordered breathing
Pataka, A., Frangulyan, R., Mackay, T. W., Douglas, N. J., & Riha, R. L. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03610.x · Cited by 47
“Most stimulants decrease appetite [31], whilst antidepressants active against cataplexy may increase appetite [32].”
BackgroundHigh H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder
Salvi, V., Barone‐Adesi, F., D’Ambrosio, V., Albert, U., & Maina, G. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4085-9 · Cited by 41
“…2010; Stubbs et al. 2015; Vancampfort et al. 2013) and at a lesser extent mood stabilizers (Yumru et al. 2006) cause weight gain and metabolic abnormalities, there are reports that also antidepressants may increase risk factors for cardiovascular morbidity (Maina et al. 2004; McIntyre et al. 2006).”
BackgroundSelf-citationAlbert, U., Salvi, V., Saracco, P., Bogetto, F., & Maina, G. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.7.970 · Cited by 52
Self-citationDecreased body mass index during treatment with sodium oxybate in narcolepsy type 1
Schinkelshoek, M. S., Smolders, I. M., Donjacour, C. E. H. M., van der Meijden, W. P., van Zwet, E. W., Fronczek, R., & Lammers, G. J. (2018) · Journal of Sleep Research · doi:10.1111/jsr.12684 · Cited by 36
Fluoxetine for adults who are overweight or obese
Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011688.pub2 · Cited by 43
Anti-brain antibodies in adult patients with obsessive–compulsive disorder
Maina, G., Albert, U., Bogetto, F., Borghese, C., Berro, A. C., Mutani, R., Rossi, F., & Vigliani, M. C. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.019 · Cited by 36
“All socio-demographic and illness characteristics were obtained through the administration of a semistructured interview, developed and used in previous studies (Bogetto et al., 1999, Albert et al., 2002, Albert et al., 2004 and Maina et al., 2004).”
Self-citationGobshtis, N., Ben‐Shabat, S., & Fride, E. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.028 · Cited by 34
Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients: An Updated Review
Watkins, C. C., Pieper, A. A., & Treisman, G. J. (2011) · Drug Safety · doi:10.2165/11592070-000000000-00000 · Cited by 37
Portman, D. J., Kaunitz, A. M., Kazempour, K., Mekonnen, H., Bhaskar, S., & Lippman, J. S. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000210 · Cited by 33
Does suffering dominate enjoyment in the animal kingdom? An update to welfare biology
Freitas-Groff, Z., & Ng, Y. (2019) · Biology & Philosophy · doi:10.1007/s10539-019-9692-0 · Cited by 36
Depressive symptoms and SSRI use in pediatric oncology patients
Kersun, L. S., & Elia, J. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21208 · Cited by 29
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“Individual randomized trials have shown a mild degree of weight gain (1%–3%) for paroxetine, escitalopram, and sertraline.(37,164) Other agents, such as fluoxetine and citalopram, appear more weight neutral.”
BackgroundDell’Osso, B. M., Allen, A., & Hollander, E. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.15.2727 · Cited by 29
“In addition, a recent 2-year follow-up study [80] in OCD patients receiving long-term treatment with different SSRIs showed a modest weight increase in a subgroup of subjects taking fluvoxamine.”
BackgroundClinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
Sertraline for the treatment of depression in coronary artery disease and heart failure
Parissis, J., Fountoulaki, K., PARASKEVAIDIS, I. A., & Kremastinos, D. T. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1529 · Cited by 26
Abejuela, H. R., & Osser, D. N. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000098 · Cited by 26
“7% of body weight during extended treatment of obsessivecompulsive disorder, versus <5%with sertraline.(64) Paroxetine is associatedwith themost sexual side effects,(65) hasmore cytochrome P450 drug interactions than escitalopram or sertraline, and can produce discontinuation symptoms if a dose is missed, due to its s…”
BackgroundGibson, M. V., Carek, P. J., & Sullivan, B. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.41.2.c · Cited by 30
Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2022) · Obesity Facts · doi:10.1159/000524995 · Cited by 28
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 29
Antidepressant‐like Effect of Insulin in Streptozotocin‐induced Type 2 Diabetes Mellitus Rats
Sestile, C. C., Maraschin, J. C., Rangel, M. P., Cuman, R. K. N., & Audi, E. A. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12563 · Cited by 18
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Antiobesity pharmacotherapy to facilitate living kidney donation
Orandi, B. J., Lofton, H. F., Montgomery, R. A., & Segev, D. L. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.12.003 · Cited by 16
Siavash, M., Kazemi, F., Najafian, A., Mohammady, M., Aminorroaya, A., & Amini, M. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803447 · Cited by 15
Pereira, J. D., Caricati‐Neto, A., Jurkiewicz, A., & Jurkiewicz, N. H. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.09.012 · Cited by 13
Pharmacological Treatment of Anxiety Disorders
Baldwin, D., & Brandish, E. K. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch43 · Cited by 9
Preconception planning to reduce the risk of perinatal depression and anxiety disorders
Avni-Barron, O., Hoagland, K., Ford, C., & Miller, L. J. (2010) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.10.27 · Cited by 15
Seo, H., Jung, Y., Woo, Y. S., Jun, T., Chae, J., & Bahk, W. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1001 · Cited by 12
Neurobiology Confirms Psychopathology
Zink, M., Englisch, S., & Dreßing, H. R. (2008) · Psychopathology · doi:10.1159/000141922 · Cited by 11
Horne, J. R., Gilliland, J., & Madill, J. (2020) · Nutrition and Health · doi:10.1177/0260106020928667 · Cited by 6
“Given the complexity of weight management (Finkelstein et al., 2005; Geiker et al., 2018; Gilliland et al., 2012; Maina et al., 2004; Moore et al., 2010; Naderpoor et al., 2015; Seabrook and Avison, 2010), simply advising individuals to ‘maintain a healthy body weight’ does not provide specific…”
BackgroundNeuropsychiatric and Behavioral Profiles of 2 Adults With Williams Syndrome
Urgeles, D., Alonso, V., & Ramos‐Moreno, T. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13m01504 · Cited by 5
Zhang, M., Huang, F., Jiang, F., Mai, M., Guo, X., Zhang, Y., Xu, Y., & Zu, H. (2022) · Medicine · doi:10.1097/md.0000000000031201 · Cited by 4
“Similarly, a nested case-control study found that the use of moderate to high daily doses of SSRIs increased the risk of developing diabetes mellitus,[29] and some reports have suggested that the longterm use of SSRIs may be associated with significant weight gain.[28,30] Most antidepressants appear to produce a 3 kg…”
BackgroundGupta, M., & Petti, T. A. (2025) · CNS Spectrums · doi:10.1017/s1092852925000161 · Cited by 2
“22 The serotonin transporter (SERT) that is responsible for serotonin reuptake into the presynaptic neuron is encoded by the SLC6A4 gene at Ch17q11.”
Rigardetto, S., Albert, U., Cori, D. D., & Maina, G. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2011.04.002 · Cited by 2
Self-citationPharmacotherapy of Obsessive‐Compulsive Disorder
Decloedt, E. H., & Stein, D. J. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch2 · Cited by 3
Severe obsessive-compulsive disorder (OCD): socio-demographic and clinical features
Rigardetto, S., Aguglia, A., Salvo, G. D., Albert, U., Bogetto, F., & Maina, G. (2013) · Clinical Management Issues · doi:10.7175/cmi.v7i2.646 · Cited by 1
Self-citationAlbert, U., Brunatto, C., Aguglia, A., Maina, G., Rocca, G., & Bogetto, F. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000543 · Cited by 2
“…attraverso l’utilizzo di un’intervista semistrutturata sviluppata e utilizzata in precedenti studi (Bogetto et al., 1999; Albert et al., 2002; 2004; Maina et al., 2004), per tutti i pazienti sono state rilevate le seguenti caratteristiche: Socio-demografiche: età, sesso, stato civile, anni di…”
BackgroundSelf-citationWat is er bekend over gewichtstoename bij gebruik van paroxetine?
Passier, J. L. M., & van Puijenbroek, E. (2006) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8808-0_1471 · Cited by 1
Psychopharmacology for Pediatric OCD and Related Disorders
Greenberg, E., Johnson, G., & GELLER, D. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_10 · Cited by 1
PSYCHIATRIC MEDICATIONS AND METABOLIC SYNDROME
Mendelson, S. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012374240-7.50007-3 · Cited by 1
Differenze di genere nel disturbo ossessivo-compulsivo: uno studio clinico su 415 pazienti
Albert, U., Aguglia, A., Barbaro, F., Cori, D. D., Maina, G., & Bogetto, F. (2012) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2012.03.004 · Cited by 1
Self-citationSavaş, E., Özovacı, A., Kokaçya, M. H., Altındağ, A., & Vırıt, O. (2010) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2010.11790677 · Cited by 1
Maina, G., Pessina, E., Asinari, G. F., Micari, J., & Bogetto, F. (2007) · Institutional Research Information System University of Turin (University of Turin) · Cited by 1
Self-citationdos Santos, M. A. B. (2013) · Americanae (AECID Library) · Cited by 1
Boisseau, C. L., & Rasmussen, S. A. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.12.017
SSRI-switch bij gewichtstoename?
de Voogd, M., Bastiaans, F., & Maarsingh, O. R. (2013) · Huisarts en Wetenschap · doi:10.1007/s12445-013-0269-x
Pharmacological Treatment with the Selective Serotonin Reuptake Inhibitors
Mochcovitch, M. D., & Baczynski, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-12538-1_15
Horne, J. R. (2020) · Scholarship@Western (Western University) · Cited by 2
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.634
Skobeleva, T. N., Savgacheva, M. Y., & Karakchiev, D. A. (2026) · Patient-Oriented Medicine and Pharmacy · doi:10.37489/2949-1924-0139 · Cited by 2
Metadata
- Authors
- Maina, G., Albert, U., Salvi, V., & Bogetto, F.
- Affiliations
- University of Turin (IT)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-10-15
- Volume
- 65
- Issue
- 10
- Pages
- 1365-1371
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034186473
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 1 · 2016: 7 · 2015: 2 · 2014: 3 · 2013: 5 · 2012: 3
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- obsessive-compulsive disorder, weight gain, clomipramine, selective serotonin reuptake inhibitors, fluoxetine, sertraline, citalopram, fluvoxamine, paroxetine, long-term antidepressant treatment, medication adherence
- MeSH terms
- Adult, Ambulatory Care, Clomipramine, Female, Fluoxetine, Follow-Up Studies, Humans, Male, Obesity, Obsessive-Compulsive Disorder, Patient Compliance, Prospective Studies, Risk Factors, Citalopram, Weight Gain, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.